Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
Portfolio Pulse from Benzinga Newsdesk
Ideaya Biosciences has dosed its first patient in a Phase 1 trial of IDE397 in combination with Gilead's Trodelvy for patients with MTAP-deletion bladder cancer.
June 25, 2024 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's Trodelvy is being used in a Phase 1 trial in combination with Ideaya's IDE397 for MTAP-deletion bladder cancer.
Gilead's involvement in the trial with Trodelvy could enhance the drug's market potential and showcase its versatility, potentially leading to a positive short-term impact on Gilead's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Ideaya Biosciences has started a Phase 1 trial of IDE397 in combination with Gilead's Trodelvy for MTAP-deletion bladder cancer.
The initiation of a Phase 1 trial is a positive development for Ideaya Biosciences, indicating progress in their clinical pipeline. This could lead to increased investor confidence and a potential short-term boost in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100